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Abstract
The treatment for non-muscle-invasive bladder cancer is transurethral resection 
of bladder cancer followed by intravesical chemotherapy or BCG. There have been 
various advancements in low risk, intermediate risk, high risk, and BCG failure 
cases of non-muscle invasive bladder cancer. There has been increased research 
on hyperthermia and intravesical chemotherapy, new agents like apaziquone, use 
of gemcitabine in low-risk cases, and combination chemotherapy in cases of BCG 
failure. Combining docetaxel and gemcitabine has taken a significant stage because 
of BCG shortage in some parts of the world. This chapter will discuss the latest 
advancements in intravesical chemotherapy in low, intermediate, and high-risk 
patients.
Keywords: Non-muscle invasive bladder cancer, Intravesical chemotherapy, 
Advancements in intravesical chemotherapy, Gemcitabine, Docetaxel, Nanoparticles, 
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1. Introduction
Bladder cancer accounts for 3% of the total cancers diagnosed in the world. It 
is more prevalent in developed countries. The most potent risk factor is tobacco 
smoking. Seventy-five percent of bladder cancer cases present with non-muscle 
invasive disease. The five-year survival statistics in the US are 69.5% for local-
ized disease, 36.3% for regional disease, and only 4.6% for metastatic disease [1]. 
Almost three-fourths of high-risk non-muscle invasive bladder cancer will have a 
recurrence within ten years, 33% will progress to invasive disease [2].
Clinical guidelines suggest a risk-stratified approach post TURBT for intravesi-
cal therapy instillation. BCG has been the gold standard for intermediate and 
high-risk diseases. However, 61% of all patients recur within one year [3, 4]. In 
low-risk patients, a single post-operative instillation is adequate. This is based on a 
meta-analysis by Sylvester et al., which showed that patients receiving post-opera-
tive chemotherapy had a decrease in 39% of odds of recurrence with chemotherapy. 
They also showed that in patients with multiple tumors single instillation was not 
successful. Patients with a single tumor had a recurrence of 35.8% vs. a recurrence 
of 65.2% in patients with multiple tumors. No difference in different chemothera-
peutic agents was found. The instillation is recommended to be given within 6 hours 
after TURBT, but in any case, within 24 hours if there is no deep resection [5].
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The intermediate-risk group of patients is the largest group of non-muscle invasive 
bladder cancer patients. Intravesical instillations are recommended to decrease the risk 
of recurrence. The combined analysis from the European Organization for Research 
and Treatment of Cancer [EORTC] and Medical Research Council [MRC] randomized 
clinical trials included 2535 patients of primary or recurrent, stage TaT1 transitional cell 
carcinoma compared transurethral resection alone with and without adjuvant intra-
vesical therapy. It showed a significant difference in terms of the duration of disease-
free survival. No significant advantage in progression was seen. The median follow-up 
for survival was 7.8 years [6]. The guidelines recommend intravesical instillations of 
chemotherapeutic agents or BCG post TURBT in the intermediate-risk group [7, 8].
A second TURBT is mandatory within 2–6 weeks in the current guidelines in the 
high-risk group [7]. Guidelines recommend BCG intravesical therapy for high-risk 
patients. This is based on a meta-analysis by Sylvester et al., which included 24 trials 
with 4863 patients. The median follow-up was 2.5 years, and the maximum follow-
up was of 15 years. In the BCG group, 260 out of 268 progressed [9.8%] while in the 
control group 304 out of 2205 progressed [13.8%]. There was a reduction of 27% 
in progression on BCG and the results were statistically significant. No significant 
benefit in disease-free survival was found [9]. No adjuvant chemotherapeutic 
regimens are included in the clinical guidelines as of now.
2. Advancements in low-risk disease
2.1 Gemcitabine
2.1.1 The rationale for using gemcitabine
Gemcitabine is 2′2’ – diflourodeoxycytidine and it has a broad spectrum of 
antitumor activity. It is phosphorylated and incorporated into DNA and RNA which 
results in apoptosis.
Many characteristics make gemcitabine a promising intravesical agent for blad-
der cancer. First, there has been a response rate of 27–38% during the systematic 
administration of gemcitabine against invasive bladder cancer. Second, the absorp-
tion of intravesical chemotherapeutic agents requires the size of the drug to be less 
than 300 Da. Gemcitabine has a molecular weight of 299 Da, which is lower than 
mitomycin and doxorubicin. It enables the drug to better penetrate the bladder 
mucosa and at the same time, the molecular weight is not too low so that systematic 
absorption of the drug occurs. The pKa of the drug is 3.6 and it results in a pH of 
2.7–3.2 after reconstitution. Therefore, it results in low ionization of the drug at the 
acidic pH of the urine [10].
2.1.2 Studies for intravesical gemcitabine
Bohle et al. conducted a double-blind placebo-controlled randomized control 
trial in low and intermediate-risk patients for post-TURBT intravesical gemcitabine 
versus placebo in 355 patients in 24 urological centers. They used a single post-
operative instillation of 2gm in 100 ml NS of gemcitabine with a 30–40 minutes 
retention time. The placebo used was 100 ml of normal saline. Both of these were 
followed by 20-hour bladder irrigation. The median follow-up was 24 months. 
Recurrence-free survival [12 months] was 77.7% in the gemcitabine group and 
75.3% in the placebo group. There was no statistical significance between the two 
groups. The authors concluded that continuous irrigation and improved TURBT 
techniques might have led to high recurrence-free survival in both groups [11].
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The SWOG SO337 randomized control trial was conducted at 23 US centers, and 
it assessed the effect of single post-operative instillation of intravesical gemcitabine 
versus saline in low-risk NMIBC cases. They used 2gm gemcitabine in 100 ml NS 
and 100 ml saline with a retention time of 1 hour in both groups. A total of 215 
patients with low-risk NMIBC were randomized. The median follow-up was four 
years. In the gemcitabine group, 34 recurred out of 102, and in the saline group, 59 
recurred out of 113 patients. There was a statistically significant difference between 
both groups [P = 0.001]. There were no grade 4 or 5 adverse events. The authors 
concluded that in low-risk non muscle-invasive bladder cancer patients, immediate 
intravesical instillation of gemcitabine significantly reduced the recurrence rate 
over a median of 4 years [12].
2.2 Apaziquone
Apaziquone is a mitomycin derivative and chemically 5-[aziridin-1-yl]-3-
[hydroxymethyl]-2-[[1E]-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione. 
It has a molecular weight of 288.30 Da. The drug product is called EOquin, and it 
has a storage temperature of 2–8 degrees Celsius. Before intravesical instillation, the 
EOquin vial is reconstituted with 20 ml of Diluent [a propylene glycol solution for 
intravesical instillation] to yield 0.2 mg/ml of apaziquone. This solution is further 
diluted with 20 ml of sterile water for injection, USP, resulting in 40 ml of the 
instillation solution containing 0.1 mg/ml of apaziquone [13].
It is the most potent intravesical agent in vitro. It is a prodrug and enzymatically 
activated by DT diaphorase [DTD] to generate cytotoxic species [13].
Karsh et al. reported two phases 2 multinational, double-blind placebo-
controlled trials in patients with Ta, G1-G2 NMIBC to evaluate the efficacy of single 
instillation of apaziquone post TURBT. These two trials [SPI -611 and SPI 612] were 
conducted between April 2007 to January 2012. A single intravesical instillation of 
apaziquone [4 mg/40 mL] or placebo was administered within 6 hours post-TURBT. 
The primary endpoint was a 2-year recurrence-free rate, and the secondary end-
point was time to recurrence. A total of 1614 patients were enrolled.
Individually the two studies did not meet any statistical significance for a 2-year 
recurrence-free rate [38.0% vs. 44.6%, 39.7% vs. 46.3%]. When the pooled analysis was 
presented, it showed a 6.7% reduction in the 2-year recurrence-free rate. [OR – 0.76, 
P – 0.0218]. In both the studies, time to recurrence showed improvement, which was 
statistically significant in the SPI-611 study. Pooled data for time to recurrence also 
showed a significant improvement of time-to-recurrence [hazard ratio [HR] 0.79; 
P5.0096]. Apaziquone is rapidly metabolized in the blood. Therefore, a post hoc analysis 
was conducted by the time window of drug instillation post TURBT. Patients who had 
drugs instilled in the time window 60 ± 30 minutes post-TURBT demonstrated 20.3% 
and 20.8% reduction in 2- in the two studies, respectively.
These studies reported the safety of this drug for intravesical instillation, but 
further studies are required for determining the efficacy of this drug [14].
3. Advancements in intermediate and high-risk disease
3.1 Heated intravesical chemotherapy
Hyperthermia is the application of mild heat [40–44-degree Celsius]. Thermal 
ablation is having a higher temperature range of 600 to 900 Celsius. Hyperthermia 
helps in triggering the immune anti-cancer response. It also helps to improve drug 
delivery and is itself also directly cytotoxic to the cancer cells [15, 16].
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The warm temperature results in local vasodilation and causes the leaky 
tumor vasculature to become leakier, resulting in improved drug delivery to the 
tumor cells. This is called the enhanced permeability and retention effect [17]. 
Hyperthermia can be provided by external devices and internal devices. Internal 
devices are most commonly used. Table 1 describes the various devices which 
are used.
Heated intravesical chemotherapy has been used in neoadjuvant and adjuvant 
settings.
3.1.1 Neoadjuvant setting
Sousa et al., conducted a pilot clinical trial in 15 patients with intermediate and 
high-risk non-muscle-invasive bladder cancer patients. HIVEC consisting of eight 
weekly instillations of intravesical mitomycin C [80 mg in 50 mL] delivered with 
the novel Combat BRS® system at a temperature of 43°C for 60 min. A total of 119 
treatments sessions were given. During TURBT it was found that 8 patients [53%] 
had a complete response and 7 [47%] had a partial response. The median follow-up 
was 29 months and the 3-year recurrence rate was 15%. No grade 3 toxicity was 
observed [18].
3.1.2 Adjuvant setting
Arends et al. conducted a phase III open-label, randomized control trial among 
190 intermediate and high-risk non-muscle-invasive bladder cancer patients. 1-yr 
hyperthermia with mitomycin C [20 mg/50 mL] for 2, 30-minute sessions for six 
weeks, and maintenance course three cycles] were administered. The primary end-
point was 24-month recurrence-free survival. The 24 months recurrence-free sur-
vival was 78.1% in the hyperthermia group and 64.8% in the BCG group [P = 0.08]. 
There was less than a 2% progression rate in both groups. No new adverse events 
were noted. In the per-protocol analysis, the 24 months recurrence-free survival 
was 81.8% in the hyperthermia group and 64.8% in the BCG group [P = 0.02]. The 
authors concluded that hyperthermia with Mitomycin C is safe and has a higher 2- 
year recurrence-free survival [21].
3.2 Ongoing trial for primary chemoablation
An ongoing phase 2 study of UGN-102 for low-grade intermediate risk non-
muscle invasive bladder cancer [OPTIMA II] has enrolled 63 participants. They 
used 75 mg Mitomycin C [mitomycin C] in 56 mL admixture [1.33 mg mitomycin 
C per 1 mL of admixture], and six intravesical instillations were given weekly. The 
Device Mechanism of action
Combat bladder recirculating system [BRS] 
[Inno Medicus, Cham, Switzerland] [18]
Externally heat fluid and the circulate it to the bladder via a 
3-way irrigating Foley catheter.
Unithermia [El Medical, Hod-Hasharon, 
Israel] [19]
Externally heat fluid and the circulate it to the bladder via a 
3-way irrigating Foley catheter.
Synergo [Tigard, OR] [20] Intravesical bladder heating system also uses recirculating 
bladder irrigation, but instead of a heat exchanger, it uses a 
microwave radiofrequency emitting intravesical catheter to 
heat the bladder.
Table 1. 
The internal devices used for hyperthermia.
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primary objective was the complete response rate three months after treatment. The 
trial completion date was December 2020, and results are awaited [22].
3.3 Gemcitabine docetaxel combination in BCG naive patients
Thomas et al. published an abstract of retrospective data for patients receiving 
sequential gemcitabine and docetaxel. The patients had not received any other 
intravesical therapy before. They were treated with six weekly instillations of gem-
citabine [1 gram of gemcitabine in 50 ml of sterile water] followed immediately by 
docetaxel [37.5 mg of docetaxel in 50 mL of saline]. Maintenance therapy was then 
given for two years in patients without recurrence. The total number of patients 
identified was 30, and the median follow-up was 18 months. The indications of 
using this combination therapy were advanced age, immunosuppression, and BCG 
shortage. Treatment success was 96% at three months, 89% at one year, and 89% at 
two years. Treatment was well tolerated [23].
3.4 Ongoing trial for BCG naïve NMIBC: GEMDOCE trial
A phase II, two-stage, open-label trial for studying the safety and efficacy of 
gemcitabine docetaxel combination has started recruitment from Jul 29, 2020. The 
estimated enrolment is 26 patients, and the estimated completion is June 2024. 
The drug combination and dosing being used is 1 g gemcitabine in 50 ml sterile 
water; instilled once weekly for six weeks and then once monthly for ≤21 months 
and 37.5 mg docetaxel in 50 ml normal saline solution [NSS]; instilled once weekly 
for six weeks and then once monthly for ≤21 months. The primary objective is 
three months’ complete response rate as assessed by cystoscopy and cytology. 
[ClinicalTrials.gov Identifier: NCT04386746] [24].
4. Advancements in BCG failure cases
4.1 Hyperthermia in BCG unresponsive cases
The HYMN trial was an open-label, two-arm, phase III randomized control trial 
in which 104 patients with BCG unresponsive non-muscle invasive bladder cancer 
were randomized to hyperthermia plus mitomycin or a second course of BCG. In the 
hyperthermia arm Synergo SB-TS 101 System was used and two 30 min cycles, each 
with 20 mg mitomycin at 420 +/− 20. Patients allocated to the BCG arm received six 
consecutive weekly BCG instillations [in 50 ml normal saline] followed by mainte-
nance therapy [three consecutive weekly instillations at 3, 6, 12, 18, and 24 months]. 
Primary outcomes were disease-free survival [DFS] and three months complete 
response for CIS patients at randomization. The median follow-up was 35 months. 
No statistically significant difference was observed between the two arms. The 
hyperthermia arm had 35% DFS, and the BCG arm had 41% DFS. [HR 1.33, 95% 
confidence.
interval [CI] 0.84–2.10], p = 0.23; adjusted p = 0.49]. There was a nonsignificant 
higher DFS favoring hyperthermia group than BCG group in non-CIS patients at 
baseline [HR 0.50, 95% CI 0.22–1.17, p = 0.11] [25].
The most adverse events in this study were grades 1–2. There was two grade 4 
toxicities in the BCG arm due to arthritis, and the other BCG-related sepsis resulted 
in death. No difference in health-related quality of life [HRQoL] was observed 
between the two treatment arms, although hyperthermia group patients reported 
their HRQoL higher than BCG group patients at 3,6 and 9 months [25].
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4.2 Docetaxel
Docetaxel as a sole agent was studied in a phase I/II trial in 54 BCG refractory 
NMIBC between 2003 and 2012. A dose-escalation scheme was used in the first 
18 patients treated with doses ranging from 5 to 75 mg for a final concentration 
of 0.125 to 0.75 mg/ml for administration. All subsequent patients received the 
maximum dose of 75 mg/100 ml of normal saline. All patients received six weekly 
instillations of intravesical docetaxel. After the phase I trial, those with a complete 
response to induction treatment were offered single dose monthly maintenance 
treatments for a total of up to 12 months of docetaxel therapy. The Median follow-
up was 39.1 months. A complete initial response was seen in 32 patients [59%]. One 
year and the three-year recurrence-free rate was 40% and 25%, respectively. The 
authors concluded that intravesical docetaxel appears to be an efficacious agent, but 
large trials are needed to fully characterize this agent’s benefits [26].
4.3 Gemcitabine and associated combinations
4.3.1 Gemcitabine as a sole agent
Gemcitabine has been studied in BCG refractory cases in two trials. Lorenzo 
et al. conducted a multi-center prospective randomized phase 2 trial in which 80 
patients failing one course of BCG were randomly allocated to Gemcitabine arm and 
2nd course of BCG arm. Kaplan Meier statistics of 2-year recurrence-free survival 
showed a significant difference between the gemcitabine and BCG group [19% and 
3%, respectively, P < 0.008]. Seven of 21 [33%] patients in gemcitabine group and 
13 of 35 [37.5%] patients in group had disease progression and underwent radical 
cystectomy [P = .12]. No significant safety concern was seen in both groups. The 
authors concluded that gemcitabine might be considered a second-line treatment 
after BCG failure in a high-risk non-muscle-invasive group [27].
Addeo et al. conducted a phase III randomized control trial in 120 high-risk 
NMIBC patients previously treated with BCG from march 2003 to November 2005. 
They received 40 mg of mitomycin C or 2000 mg of gemcitabine diluted in 50 mL 
of normal saline. The median follow-up was 36 months. In the gemcitabine arm, 
39 of 54 patients remained free of recurrence versus 33 of 55 in the mitomycin 
C arm. Progression was seen in 10 patients in the mitomycin C arm and 6 in the 
gemcitabine arm. The incidence of chemical cystitis in the mitomycin C arm was 
statistically higher than in the gemcitabine arm [P = .012] [28].
These studies show that gemcitabine alone or combined can be consid-
ered in BCG refractory high-grade disease if cystectomy is contraindicated or 
refused [29].
4.3.2 Gemcitabine plus cabazitaxel plus cisplatin
A phase I trial studied the effect of this combination therapy. The trial was a 
dose-escalation, drug escalation study in patients of high-risk BCG failure NMIBC. 
A total of 18 patients were included, and the median follow-up was 27.8 months. 
The schedule used was
• 6-wk induction regimen of sequentially administered cabazitaxel, gemcitabine, 
and cisplatin
• Responders continued with maintenance cabazitaxel and gemcitabine monthly 
for the first year and bimonthly for the second year.
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The dosing used in this study was:
1. Gemcitabine- 2 g/100 ml, Cabazitaxel – 5 mg/100 ml, Cis – 66 mg/100 ml
2. Gemcitabine- 2 g/100 ml, Cabazitaxel – 5 mg/100 ml, Cis – 80 mg/100 ml
3. Gemcitabine- 2 g/100 ml, Cabazitaxel – 5 mg/100 ml, Cis – 100 mg/100 ml
A complete response rate of 94% was observed, and a DFS of 78% was observed 
at 9.5 months. No Dose-limiting toxicity till the last follow-up. Further studies need 
to be done to evaluate the efficacy of this combination.
4.3.3 Gemcitabine plus mitomycin
This combination was first used in 2006, and it showed promising results in 
BCG failure patients. There were 20 months of median disease-free survival in the 
study by Maymi et al. [30].
In a retrospective study conducted by Cockerill et al., 27 patients with BCG 
failure were identified and had received gemcitabine plus mitomycin combination 
therapy. With a median follow-up of 22.1 months, ten patients had no recurrence. 
The authors concluded that this combination could offer durable recurrence-free 
survival to patients with recurrent NMIBC who are not candidates for, or refuse, 
cystectomy [31].
Similarly, Lightfoot et al. showed in a retrospective review of 47 patients who 
received six weekly treatments with sequential intravesical gemcitabine [1 g] and 
MMC [40 mg] chemotherapy for NMIBC. The median time for follow-up was 
26 months. Fourteen of 47 patients [30%] remained free of recurrence. These stud-
ies show that gemcitabine plus mitomycin combination can be helpful in high-risk 
BCG failure NMIBC cases.
4.3.3.1 Administration of gemcitabine plus mitomycin combination
Patients should be pre-treated with an oral urinary alkalization agent [such as 
sodium bicarbonate the night before and the morning of installation]. Gemcitabine 
does not directly irritate the bladder, but its solution is very acidic [pH - 2.6], whereby 
Mitomycin C is inactivated under acidic conditions, and it irritates the bladder.
Patients receive six weekly intravesical installations for induction, which 
includes administration of the following:
1. 1 g Gemcitabine is diluted in 50 mL normal saline [Dwell time: 90 minutes]
2. The bladder is drained without rinsing
3. Instill 40 mg Mitomycin is diluted in 20 mL sterile saline [Dwell time 
90 minutes]
Monthly maintenance administrations are generally given for 1 to 2 years or until 
recurrence [31, 32].
4.3.4 Gemcitabine plus docetaxel
Docetaxel inhibits mitosis and cell division by inhibiting the microtubular 
assembly [33]. Preclinical studies have shown that gemcitabine acts as an exfoliant 
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for urothelial cells. This increases the penetration of docetaxel and therefore has 
enhanced efficacy [34].
Retrospective studies have shown that this combination is a promising intra-
vesical combination in BCG failure cases. Milbar et al. showed in a retrospective 
analysis of 33 BCG unresponsive patients that 1-year recurrence-free survival [RFS] 
is 49% and 34% in 2 years [35]. Steinberg et al., in another retrospective analysis of 
45 patients, showed treatment success of 66% at first surveillance, 54% at one year, 
and 34% at two years [36].
Steinberg et al. presented the preliminary results from a multi-institutional 
retrospective study of 276 BCG failure patients. The median follow-up was 
22.9 months. Recurrence-free survival after 1 and 2 years was 60% and 46%, 
respectively. High-grade recurrence-free survival rates were 65% and 52%, 
 respectively [37].
4.3.4.1 Administration of gemcitabine and docetaxel
The patient should be pre-treated with an oral alkalinizer. Pre-treatment with 
ondansetron helps to control gemcitabine-induced vomiting. Six intravesical instil-
lations are given for induction as follows:
• 1 gm gemcitabine in 50 ml NS with a dwell time of 90 minutes.
• The bladder is drained without rinsing.
• 40 mg of docetaxel is diluted in 50 ml NS and given intravesical with a dwell 
time of 90–120 minutes.
Monthly maintenance is given 1–2 years [36, 37].
5. Nanoparticles
One nanometer is the scale at which many of the biological molecules operate 
inside the living cells. Nanoparticles accumulate in tumor tissues. This occurs via the 
enhanced permeability and retention [EPR] effect because the tumor tissues have a 
more permeable vascular supply, and this allows the nanoparticles to enter the cell. 
Nanoparticles can be used for the encapsulation of poorly soluble drugs [38].
Abraxane - nanoparticle albumin-bound version of paclitaxel. Nanoparticle 
albumin bound-paclitaxel has five times higher solubility as compared to docetaxel. 
Mckiernan et al. have studied this nanoparticle albumin-bound paclitaxel in 28 patients 
in a phase I single-center trial. Complete response was seen in 10 patients. The Median 
follow-up was 21 months. There was no progression in 19 out of28 patients. Their 
adverse events were limited to grades 1 and 2. The authors concluded that intravesical 
nab-paclitaxel had a 35.7% response rate in patients with NMIBC and BCG failure.
6. Future directions
After many years of stagnation, multiple new therapies are being investigated 
as potential intravesical agents for NMIBC. Strict criteria to define the disease have 
encouraged trials for patients with NMIBC. Most active trials focus on high-risk NMIBC 
in BCG naïve and BCG failure settings [39]. Multiple combination therapies continue to 
emerge. Table 2 shows the various ongoing trials based on intravesical chemotherapy.
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Trial Phase Drug used Trial number
Neoadjuvant Short-term Intensive 
Chemoresection Versus Standard Adjuvant 
Intravesical Instillations in NMIBC
III Mitomycin C NCT03348969
CALIBER - A Phase II Randomized Feasibility 
Study of Chemoresection and Surgical 
Management in Low Risk Non-Muscle Invasive 
Bladder Cancer
I Mitomycin C NCT02070120
A Randomized, Single-Dose, Double-Blind, 
Placebo-Controlled Phase 3 Study of Qapzola™ 
[Apaziquone] as a Chemotherapy Adjuvant 
to Transurethral Resection of Bladder Tumors 
in Patients with Low- To-Intermediate-Risk 
NMIBC [CONQUER]
III Apaziquone NCT03224182 
CONQUER
Evaluation of Immediate Preoperative 
Instillation [IPOI] of Mitomycin C Compared 
to Early Post-operative Instillation [IPOP] in 
Non-muscle Invasive Bladder Cancer
III Mitomycin C NCT02075060
A Phase 1/2a Pilot Study of Intravesical TSD-001 
for Treatment of Low-Grade, Stage Ta, Non-
Muscle Invasive Bladder Cancer
I TSD-001 NCT03081858
A Prospective, Open-label Randomized 
Clinical Trial of a Single Bladder Instillation of 
Mitomycin C vs. Gemcitabine vs. No Additional 
Treatment Immediately After Transurethral 
Resection of Bladder Tumor [TURBT]
III Mitomycin C 
Gemcitabine
NCT02695771
The Effectiveness and Safety of Neoadjuvant 
Intravesical Mitomycin-C Instillation in 
Non-muscle Invasive Bladder Cancer Patients: 
Prospective, Randomized, Phase II Study
III Mitomycin C NCT03058757
Open clinical trial to evaluate the efficacy of 
intravesical instillation of hyaluronate added 
to early instillation of mitomycin vs. early 
instillation of mitomycin in patients suffering 







A Phase 1b, Multicenter, Open Label Study 
Evaluating Safety, Tolerability and Preliminary 
Efficacy of GemRIS 225 mg in Subjects with 
Non-Muscle-Invasive Urothelial Carcinoma of 
the Bladder
III Gemcitabine NCT02720367
Randomized prospective clinical trial to 
evaluate the rate of early recurrence in non-
muscle invasive bladder cancer between the 
chemohyperthermia [QH] with mitomycin-C 
prior to transurethral resection of bladder in 
ambulatory surgery program and post resection 
treatment with mitomycin C in normothermia.
III Mitomycin C EUCTR2015–005151-
27
HIVEC HR: Use of chemohyperthermia with 
intravesical mitomycin [HIVEC] for the 
treatment of patients with NMIBC




HIVEC [Hyperthermic IntraVesical 
Chemotherapy] for Patients with Intermediate 
Risk NMIBC Compared with Standard 
Intravesical Instillation Of Chemotherapy 
As Adjuvant Treatment. A Comparative, 
Prospective, Randomized Study.
III Mitomycin C EUCTR2013–002628-
18
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Food and drug administration gave guidelines on designing trials in NMIBC as 
follows: [40].
• High-risk NMIBC
1. Trials can include a mix of high risk and CIS cases
2. Time to an event is the preferred endpoint
3. Placebo-controlled trials of BCG are not helpful.
4. The duration of follow-up should be at least 18–24 months.
• High-risk BCG refractory
1. No standard of care in this group.
2. Single-arm trials can be used if they provide robust results
3. Patients having BCG refractory CIS should have a complete response rate of 
40–50% at six months and at least 30% response rate at 18–24 months.
• Placebo trials
These can be used in low-risk patients.
• Perioperative intravesical instillation agents
1. Time to event analysis should be used
2. Follow-up of at least two years
3. The clinically meaningful result is defined as a 15% event rate reduction or a 
hazard ratio of 0.7.
Trial Phase Drug used Trial number
A Phase 3 Study to Evaluate the Efficacy 
and Safety of Intravesical Nanoxel®M 
[Docetaxel-PM] In Bacillius Calmette-Guerin 




A Phase I Trial for the Use of Intravesical 
Cabazitaxel, Gemcitabine, and Cisplatin 
[CGC] in the Treatment of BCG-Refractory 






A Multi-center, Single-Arm Study Evaluating the 
Efficacy of Synergo® Radiofrequency-Induced 
Thermochemotherapy Effect [RITE] With 
Mitomycin C [Synergo® RITE + MMC] in CIS 
Non-Muscle Invasive Bladder Cancer [NMIBC] 
Bacillus Calmette-Guérin [BCG]-Unresponsive 
Patients with or without Papillary NMIBC




The ongoing clinical trials based on intravesical chemotherapeutic agents.
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7. Conclusion
The Table 3 and Figure 1 summarizes the various advancements in intravesical 
chemotherapy in NMIBC and Figure 1 also gives the intravesical chemotherapy of 
choice in various risk categories.
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Appendices and nomenclature
European association of urology 2021 non-muscle invasive bladder cancer risk 
stratification:
Risk Advancement
Low risk • Gemcitabine can also be used as a 1st line agent for single instillation 
post TURBT
Intermediate and high-risk 
BCG naive
• Single agent - HIVEC + MMC show favorable response.
• Combination – Gemcitabine + Docetaxel combination is under research
BCG failure • Gemcitabine alone or in combination can be if cystectomy is contrain-
dicated or refused.
Table 3. 
Summary of the various advancements in intravesical chemotherapy in NMIBC.
Figure 1. 
EAU risk stratification based intravesical chemotherapy of choice in various risk categories.
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Risk group stratification and Characteristics
1. Low-risk tumors - Primary, solitary, TaG1 [PUNLMP, LG*], < 3 cm, no CIS.
2. Intermediate-risk tumors - All tumors not defined in the two adjacent 
categories
3. High-risk tumors - Any of the following:
• T1 tumor
• G3 [HG**] tumor
• carcinoma in situ [CIS]
• Multiple, recurrent and large [> 3 cm] TaG1G2/LG tumors [all features must 
be present]
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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